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Impairment of ribosomal biogenesis can activate the p53 protein
independently of DNA damage. The ability of ribosomal proteins L5,
L11, L23, L26, or S7 to bind Mdm2 and inhibit its ubiquitin ligase
activity has been suggested as a critical step in p53 activation under
these conditions. Here, we report that L5 and L11 are particularly
important for this response. Whereas several other newly synthe-
sized ribosomal proteins are degraded by proteasomes upon in-
hibition of Pol I activity by actinomycin D, L5 and L11 accumulate in
the ribosome-free fraction where they bind to Mdm2. This selective
accumulation of free L5 and L11 is due to their mutual protection
from proteasomal degradation. Furthermore, the endogenous,
newly synthesized L5 and L11 continue to be imported into nucleoli
even after nucleolar disruption and colocalize with Mdm2, p53, and
promyelocytic leukemia protein. This suggests that the disrupted
nucleoli may provide a platform for L5- and L11-dependent p53
activation, implying a role for the nucleolus in p53 activation by
ribosomal biogenesis stress. These ﬁndings may have important
implications with respect to understanding the pathogenesis of dis-
eases caused by impaired ribosome biogenesis.
proteasome | ribosomal stress
The exposure of cells to various stressors activates the p53 tu-mor suppressor, a transcription factor that regulates many
coding and noncoding genes, with ensuing cellular outcomes such
as cell cycle arrest, apoptosis, senescence, metabolic changes, and
DNA repair (1, 2). Disruption of these functions promotes
checkpoint defects, genomic instability, illegitimate survival,
continuous proliferation, and evolution of stress-damaged cells
(2). Given the fact that loss of wild-type p53 provides many se-
lective advantages to cells, it is not surprising that ∼50% of all
human cancers have mutations within the TP53 gene (3). In
cancers retaining wild-type p53, the functions of p53 are likely
inactivated by defects in its upstream regulators and downstream
targets. Although DNA damage is common to most p53-activat-
ing stresses, evidence accumulated over the last decade suggests
that perturbation of ribosome biogenesis triggers a p53-activating
signaling pathway independently of DNA damage (2, 4–7). It was
originally suggested that this pathway has a prominent role in
preventing diseases by monitoring the ﬁdelity of ribosome bio-
genesis (4). However, recent evidence suggests that p53 activation
upon impairment of ribosome biogenesis might be responsible for
speciﬁc pathological manifestations in mammals (8–11). Earlier
work suggested that perturbation of ribosome biogenesis causes
nucleolar disruption and translocation of a number of ectopically
expressed ribosomal proteins (RPs), including L5, L11, L23, L26,
and S7, from the nucleolus to the nucleoplasm, where they bind to
Mdm2 and inhibit its ubiquitin ligase function toward p53, leading
to p53 up-regulation (6, 12–21). An alternative model proposes
that inhibition of ribosome biogenesis leads to speciﬁc up-regu-
lation of L11 mRNA translation, resulting in the accumulation of
ribosome-free L11 in the nucleoplasm where it associates with
Mdm2 and blocks Mdm2-mediated p53 ubiquitination and deg-
radation (22).
Here we demonstrate the central importance of L5 and L11
for p53 activation by pharmacological or siRNA-mediated in-
hibition of ribosome biogenesis and provide molecular insights
into this mechanism.
Results
Speciﬁc Requirement for L5 and L11 in p53 Up-Regulation by
Ribosomal Stressors. A549 human lung carcinoma cells were
transfected with siRNAs against the indicated RPs and treated
with 5 nM actinomycin D (ActD), which selectively inhibits RNA
polymerase I (Table S1). The effective silencing of each RP in all
experiments was conﬁrmed by quantitative RT-PCR (qRT-PCR)
and immunoblotting (Fig. S1 A and B; Table S2).
Down-regulation of L5 or L11, alone or together, dramatically
inhibited ActD-driven induction of p53 protein and of its targets
p21WAF1 and Mdm2 in A549 cells (Fig. 1A and Fig. S2A). In
contrast to L5 or L11, depletion of S7, L23, or L26 did not reduce
p53 accumulation (Fig. 1A). While this article was in preparation,
Fumagalli et al. reported a similar observation, except that in their
experiments S7 or L23 depletion partially inhibited ActD-induced
up-regulation of p53 (23). Moreover, depletion of L5 or L11, but
not of S7, L23, or L26, largely rescued the entry of ActD-treated
cells into the S phase of the cell cycle (Fig. S2B). Similar re-
quirements for L5 and L11 were observed in ActD-treated U2OS
cells (Fig. S2C), and a second set of siRNAs against the indicated
RPs in A549 cells provided essentially analogous results (Fig.
S2D). Together, these results provide strong evidence that under
the conditions used L5 and L11, but not S7, L23, or L26, are re-
quired for ActD-mediated induction of p53 protein and its bi-
ological activities. Furthermore, the induction of p53 and its
targets p21WAF1 and Mdm2 by 5-ﬂuorouracil (5-FU), another
pharmacological inhibitor of ribosome biogenesis, was dependent
on L5 and L11, but not on L23, L26, and S7, in both A549 and
U2OS cells (Fig. S2 E and F). Earlier studies have shown that
down-regulation of S6 inhibits 40S ribosome biogenesis and
consequently activates the p53 response in an L11-dependent
manner (4, 9, 22). Here, we found that S6 down-regulation
requires both L5 and L11, but not S7, L23, or L26, for the in-
duction of p53, p21WAF1, and Mdm2 (Fig. S2G). Consistent with
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one recent published study (23) and in contrast to other studies
(6), impairment of ribosome biogenesis by depletion of S7, L23, or
L26 led to up-regulation of p53, p21WAF1, and Mdm2 protein
levels (Fig. S2H–J). These responses were speciﬁcally inhibited by
L5 or L11 siRNAs, most likely by a mechanism similar to that
operating upon down-regulation of S6 or ActD and 5-FU treat-
ments (Fig. S2 H–J). Together, these results strongly point to
a critical role of L5 and L11 in p53 up-regulation by impairement
of ribosome biogenesis at various steps.
Accumulation of Ribosome-Free L5 and L11 upon Ribosomal Stress. It
has been proposed that upon disruption of ribosome biogenesis
several RPs, including L5, L11, S7, L23, and L26, accumulate
outside of ribosomes and participate in p53 up-regulation (6). In
light of our observations highlighting the centrality of L5 and L11
for p53 up-regulation in response to ribosomal stressors, we
evaluated the expression of endogenous ribosome-free RPs in
A549 cells by isolating ribosomal and nonribosomal cytoplasmic
and nuclear fractions that were subjected toWestern blot analysis
with the indicated anti-RP antibodies developed in our laboratory
(24) (Fig. 1B). Strikingly, whereas S3, S7, S20, L12, L23, and L26
remained exclusively associated with ribosomes after exposure to
the indicated ribosomal stressors, we detected a signiﬁcant in-
crease in the amount of ribosome-free L5 and L11 in the cyto-
plasm (Fig. 1B, Left) and nucleoplasm under the same conditions
(Fig.1B, Right), without a corresponding decrease in their
amounts in the ribosome fractions. p53, Mdm2, and p21WAF1
were also present in the nonribosomal fraction. The observation
that accumulation of ribosome-free L5 and L11 also occurred in
mouse embryonic ﬁbroblasts (MEFs) established from 13.5-d
embryos upon ActD treatment suggests that this response has
a wide biological signiﬁcance (Fig. S3A). Overexpression experi-
ments have shown that a number of RPs, including L5, L11, S7,
L23, and L26, can bind to Mdm2 and inhibit its ubiquitin ligase
activity, leading to p53 up-regulation (6, 12–21). We therefore
evaluated the interactions of several endogenously expressed RPs
with Mdm2 in total cell lysates from untreated and ActD-treated
A549 cells. We were able to coimmunoprecipitate L5, L11, S7,
L23, and L26 withMdm2 in untreated cells, and these interactions
were signiﬁcantly increased by ActD treatment most likely due to
the increased amounts of cellular Mdm2 (Fig. S3B). S6 was also
bound to Mdm2 under these conditions (Fig. S3B). This, together
with the observation that L5 and L11 are present in the non-
ribosomal fraction with Mdm2 upon ribosomal stresses (Fig. 1B),
raised the question of the speciﬁcity of interactions of endogenous
L23, L26, and S7 with Mdm2 in the total cell lysate. To address
this issue, we homogenized untreated or ActD-treated A549 cells
under conditions in which rRNA is protected from degradation,
separated ribosomal and nonribosomal fractions, and retrieved
endogenousMdm2-RP complexes from the nonribosomal fraction
(24) (Fig. 1C). As expected, Mdm2 levels were undetectable in
untreated cells and were dramatically increased after ActD treat-
ment. Mdm2 was associated with L5, L11, and p53 in this fraction.
The speciﬁcity of these interactions was further supported by the
observation that S6, S7, L23, or L26 did not form complexes with
Mdm2 under the same conditions (Fig. 1C). Both L5 and L11
immunoprecipitates contained L5, L11,Mdm2, and p53 (Fig. 1C).
The inefﬁcient coimmunoprecipitation of L11 with L5 could re-
ﬂect interference of these antibodies with formation of the L5-
L11 complex. Altogether, these results further strengthen the
critical role of L5 and L11 in p53 up-regulation by various defects
in ribosome biogenesis (Fig. 1; Figs. S2 and S3).
DeNovo Protein Synthesis Is Absolutely Required for the Accumulation
of Ribosome-Free L5 and L11 upon Ribosomal Stress. As mentioned
above, two opposing models regarding the source of p53-acti-
vating ribosome-free RPs have been put forth. One proposes
that perturbation of ribosome biogenesis causes nucleolar dis-
ruption and translocation of a number of RPs from the nucleolus
into the nucleoplasm (6), and the other suggests that there is
a selective up-regulation of L11 mRNA translation without dis-
ruption of nucleolar integrity (22). To identify the source of ri-
bosomal stress-induced endogenous ribosome-free L5 and L11,
we ﬁrst focused on nucleoli. We showed that the production of
47S rRNA, a fundamental step in ribosome biogenesis (9), was
inhibited by all tested p53-activating ribosomal stressors (Fig.
S4A). It was shown that depletion of these RPs inhibits rRNA
processing at various levels (4, 25). Despite interference with
ribosome biogenesis, L23 and L26 depletion did not show any
obvious effect on nucleolar structure visualized by ﬂuorescence
microscopy with antibodies against UBF, B23, and ﬁbrillarin
(Fig. S4B). On the other hand, depletion of either S6 or 5-FU
treatment diminished nucleolar B23 staining and resulted in its
diffused nucleoplasmic staining, whereas the localization of UBF
and ﬁbrillarin was not affected. S7 depletion speciﬁcally affected
the localization of B23, which formed nuclear spot structures.
ActD caused virtually complete nucleolar disruption, which is
characterized by formation of nucleolar caps for both UBF and
ﬁbrillarin and translocation of B23 from the nucleolus to the
nucleoplasm (Fig. S4B). The relative distribution of B23 between
nucleolus and nucleoplasm upon exposure to various ribosomal
stressors is shown in Fig. S4C. However, the observed morpho-
logical and functional changes in the nucleolus may not neces-
sarily lead to the release of L5 and L11 from the nucleolus to the
nucleoplasm. To clarify this issue, nucleoli from untreated and
ActD-treated A549 cells were isolated, and the amount of en-
dogenous nucleolar L5 and L11 was determined by Western blot
analysis (26) (Fig. 2A). Surprisingly, ActD treatment did not
substantially change the levels of nucleolar L5 and L11 (Fig. 2A),
whereas it led to a loss of nucleolar S6 and S7. To provide further
Fig. 1. Speciﬁc requirement for L5 and L11 in p53
up-regulation upon inhibition of ribosome bio-
genesis in A549 cells. (A) Cells were transfected with
the indicated siRNAs or scrambled (scr) negative
control siRNA for 48 h and treated with ActD for
16 h. Expression of the indicated proteins was con-
ﬁrmed by immunoblotting. (B) Cells were trans-
fected with the indicated siRNAs for 48 h or treated
with ActD or 5-FU for 16 h. Ribosomal and non-
ribosomal (nonrib) cytoplasmic (Left) or ribosomal
and nonribosomal nucleoplasmic fractions (Right)
were immunoblotted with the indicated antibodies.
The per-cell ratio of the amount of protein loaded
onto a gel for cytoplasmic ribosomal, nucleoplasmic
ribosomal, cytoplasmic nonribosomal, and nucleo-
plasmic nonribosomal fractions was 1:10:3:10. Tu-
bulin (tub.) was used as a cytoplasmic marker and
PARP as a nucleoplasmic marker. (C) Nonribosomal
fractions from untreated and ActD-treated cells were immunoprecipitated with the indicated antibodies. These immunoprecipitates and the total cell lysate
(TCL) from ActD-treated A549 cells were immunoblotted with the indicated antibodies.
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support for this ﬁnding, we used H1299 cells that were engi-
neered to contain L11 fused to yellow ﬂuorescent protein (YFP),
expressed from its endogenous chromosomal location (27). Con-
sistent with the results shown in Fig. 2A, confocal laser scanning
microscopy (CLSM) demonstrated that the YFP-L11 signal was
still present in the nucleolar remnants surrounded by ﬁbrillarin
cap structures in ActD-treated cells (Fig. 2B). These results imply
that the nucleolus is not a signiﬁcant source of endogenous ri-
bosome-free L5 and L11 in response to ribosomal stress. Thus,
experiments in which overexpressed RPs were used must be
interpreted cautiously (6). Next, we focused on protein synthesis.
To determine whether de novo protein synthesis is required for
the accumulation of ribosome-free L5 and L11, A549 cells were
treated for 1, 2, or 5 h with ActD (Fig. 2C) in the presence or
absence of the protein synthesis inhibitor cycloheximide (CHX).
Treatment with CHX abrogated the accumulation of ribosome-
free L5 and L11 in response to ActD (Fig. 2C) as well as the
increases in p53, Mdm2, and p21WAF1 protein levels. RP mRNAs
contain an oligopyrimidine tract at their 5′ end (5′ TOP), and the
mTOR inhibitor rapamycin prevents the translation of 5′ TOP
mRNAs (28). Similar to CHX, rapamycin prevented the accu-
mulation of ribosome-free L5 and L11 as well as p53, Mdm2, and
p21WAF1 by ActD (Fig. S4D). Together, these results demonstrate
that new protein synthesis is absolutely required for the accu-
mulation of ribosome-free L5 and L11 after inhibition of ri-
bosome biogenesis.
Ribosome-Free L5 and L11 Are Not Degraded by Proteasomes upon
ActD Treatment. RPs continue to be synthesized upon inhibition
of rRNA transcription by ActD and are rapidly degraded by
proteasomes, probably to prevent deleterious effects of highly
basic ribosome-free RPs on the cell (29–31). However, the ob-
served accumulation of ribosome-free L5 and L11 in the cyto-
plasm and nucleoplasm upon exposure to various stressors that
impair ribosome biogenesis suggests that these two RPs have
a different fate than other RPs (Fig. 1B and Fig. S3A). To assess
the stability of newly synthesized L5 and L11 upon ribosomal
stress, A549 cells were treated with ActD for 5 h, then CHX was
added for the indicated times, and the ribosome-free fraction
was analyzed by immunoblotting with the indicated anti-RP
antibodies (Fig. S5A). After up to 1 h of CHX treatment, L5 and
L11 protein levels remained unchanged (Fig. S5A). By 2 h after
addition of CHX, the amounts of ribosome-free L5 and L11
were partially decreased and became almost undetectable by the
4-h time point (Fig. S5A). On the basis of overexpression
experiments, it has been suggested that Mdm2 protects L11 from
degradation upon ActD treatment (32). To determine the extent
to which this mechanism contributes to accumulation of ribo-
some-free L5 and L11 upon ActD treatment, we prevented
Mdm2 expression by silencing its transcriptional activator, p53
(Fig. S5B). Endogenous ribosome-free L5 and L11 accumulated
normally under such conditions, suggesting that Mdm2 does not
play a role in their stabilization (32). In view of the relative
stability of L5 and L11, we hypothesized that newly synthesized
endogenous ribosome-free L5 and L11 are not degraded by the
proteasome upon exposure to ActD, in contrast to other newly
synthesized ribosome-free RPs. To test this, A549 cells were
treated with ActD, and the fate of the indicated RPs was fol-
lowed in the presence or absence of the proteasome inhibitor
MG132 (Fig. 3A). MG132 treatment resulted in a signiﬁcant
elevation of ActD-induced p53 and Mdm2 protein levels. How-
ever, the treatment did not increase the amount of ribosome-free
L5 and L11, consistent with the idea that they are not degraded
by the proteasome. Intriguingly, under these conditions, L23, S7,
S6, and S12 also did not accumulate in the ribosome-free frac-
tion in the presence of MG132 and ActD (Fig. 3A), suggesting
that they may be degraded through a proteasome-independent
pathway. Alternatively, these RPs might be normally degraded
by proteasomes upon ActD treatment, but they form insoluble
aggregates when their proteosomal degradation is inhibited by
MG132. To distinguish between these possibilities, we used
H1299 cells containing endogenous L11 or S6 fused to YFP.
Consistent with the results shown in Fig. 2A, ActD treatment led
to a complete loss of nucleolar YFP-S6, but did not signiﬁcantly
decrease the total amount of nucleolar YFP-L11 (Fig. 3B). Al-
though ActD treatment in combination with MG132 did not
have a signiﬁcant effect on the intensity and localization of the
L11-YFP signal, it caused a dramatic accumulation of nuclear
Fig. 2. De novo protein synthesis of L5 and L11 is required for their accumulation in the ribosome-free form. (A) A549 cells were left untreated or
treated with ActD for 5 h. Puriﬁed nucleoli were immunoblotted with the indicated antibodies. (B) H1299 cells containing YFP-L11 (green) were
treated with ActD for 5 h, stained with antiﬁbrillarin antibodies (red), and analyzed by CLSM. Fibrillarin nucleolar caps are indicated by arrowheads.
Nuclei are outlined with dashed lines. (Scale bar, 5 μm.) (C ) A549 cells were treated with ActD in the presence or absence of CHX for 1, 2, or 5 h, and
nonribosomal fractions were immunoblotted with the indicated antibodies.
Fig. 3. Ribosome-free L5 and L11 are not de-
graded by proteasomes upon ActD treatment. (A)
A549 cells were treated with ActD for 5 h in the
presence or absence of MG132. Nonribosomal
fractions were immunoblotted with the indicated
antibodies. (B) H1299 cells expressing YFP-L11 or
YFP-S6 were transfected with HA-Ub for 24 h and
then treated as indicated for 6 h, followed by
staining with anti-HA antibody (red) and analysis
by CLSM. (Scale bar, 5 μm.)
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aggregates containing YFP-S6 (Fig. 3B). Furthermore, ActD
treatment in combination with MG132 led to the nucleoplasmic
accumulation of YFP-L4 aggregates (Fig. S6A). Notably, the
protein synthesis inhibitor CHX prevented the formation of
YFP-S6 and YFP-L4 nucleoplasmic aggregates (Fig. 3B and Fig.
S6A). Despite the fact that proteasome inhibition by MG132
led to the nucleoplasmic accumulation of YFP-S6 and YFP-L4
aggregates in ActD-treated cells, we failed to observe their
colocalization with HA-ubiquitin (HA-Ub) (Fig. 3B and Fig.
S6A), suggesting that YFP-S6 and YFP-L4 are degraded through
a proteasome-dependent, ubiquitin-independent pathway (33).
In contrast, HA-Ub colocalized with p53, a known ubiquinated
protein, upon proteasome inhibition in A549 cells (Fig. S6B) (1).
Signiﬁcantly, endogenous S6 and S12 also formed nucleoplasmic
aggregates in the presence of ActD and MG132 (Fig. S6C). The
most likely explanation of why endogenous S6 and S12 were not
detected in the nonribosomal fraction under these conditions
(Fig. 3A) is that S6 and S12 aggregates were removed by ultra-
centrifugation. Together, these results showed that newly syn-
thesized L5 and L11 are not proteasomally degraded upon ActD
treatment, in contrast to other tested RPs, and as a consequence
they accumulate in free form.
Accumulation of Ribosome-Free L5 and L11 Is due to Their Mutual
Protection from Proteasomal Degradation. On the basis of over-
expression experiments it was previously suggested that L5 and
L11 can interact with Mdm2 independently of each other, and
their cooperative binding to Mdm2 is needed for full p53 up-
regulation (21). To gain further insight into the mutual de-
pendence of L5 and L11 in p53 activation, we silenced either L5
or L11 and followed their expression in the nonribosomal fraction
after ActD treatment (Fig. 4A). Surprisingly, L5 silencing abro-
gated the presence of L11 and vice versa (Fig. 4A). Therefore, we
tested the possibility that L5 and L11 stabilize each other in
ActD-treated cells. H1299 cells containing YFP-L11 were trans-
fected with siL5 and treated with ActD in the presence or absence
of MG132. Depletion of L5 resulted in the loss of nucleolar YFP-
L11 staining in ActD-treated cells. MG132 not only prevented the
YFP-L11 loss but also resulted in a net increase of nucleolar
YFP-L11 in siL5- and ActD-treated cells (Fig. 4B). Notably,
under these conditions HA-Ub did not colocalize with YFP-L11
(Fig. 4B). The rescue of YFP-L11 expression in siL5- and ActD-
treated cells by MG132 was prevented by CHX (Fig. 4B). These
results strongly indicate that ribosome-free L5 is required to
prevent degradation of newly synthesized L11 upon ActD treat-
ment through a proteasome-dependent, ubiquitin-independent
pathway (Fig. 4 A and B) (33).
Newly Synthesized L5 and L11 Are Imported into Nucleoli upon ActD
Treatment. The fact that the amount of nucleolar L5 and L11 in
ActD-treated A549 cells is signiﬁcantly decreased by CHX in-
dicates that newly synthesized L5 and L11 continue to accumulate
in nucleoli upon ribosomal stress (Fig. S7A). To provide further
support for this ﬁnding, we compared the dynamics of nucleoar
recovery of YFP-L11 between untreated and ActD-treated H1299
cells by using ﬂuorescence recovery after photobleaching (7, 27,
30). In the presence of ActD, we observed a signiﬁcant recovery
of ﬂuorescent YFP-L11 in the nucleoli after photobleaching.
Notably, CHX abolished that recovery (Fig. 5A and Fig. S7B),
arguing that it was dependent on de novo protein synthesis
rather than on import of preexisting protein. The newly synthe-
sized YFP-L11 colocalized with ﬁbrillarin and UBF in untreated
cells (Fig. S8A). On the other hand, in ActD-treated cells, it
localized in the nucleolar remnant (central body) in an RNA-
dependent manner and was surrounded by ﬁbrillarin and UBF
cap structures (Fig. S8A).
Newly Synthesized L5 and L11 Colocalize with p53, Mdm2, and
Promyelocytic Leukemia in the Nucleolus upon Ribosomal Stress.
The observation that newly synthesized L5 and L11 accumulate
in nucleoli upon ActD treatment suggests that they may play
a role in p53 activation at that subnuclear location. To gain in-
sight into this, we ﬁrst tested the expression of endogenous p53
and Mdm2 in highly puriﬁed nucleoli from untreated and ActD-
treated A549 cells by immunoblotting (Fig. 5B). Because the
promyelocytic leukemia (PML) tumor suppressor forms nucleolar
caps upon low-dose ActD treatment and regulates p53 acetyla-
tion at K382 (34, 35), we also tested the expression of nucleolar
PML and p53 acetylated at K382 (ac-p53) under the same con-
ditions (Fig. 5B). ActD treatment led to increased levels of nu-
cleolar p53, ac-p53, Mdm2, and PML (Fig. 5B). CLSM conﬁrmed
localization of these proteins within the abberant nucleoli of
ActD-treated A549 and H1299 cells (Fig. S8B). Under these
conditions, a portion of Mdm2 and p53 colocalized with UBF,
forming nucleolar cap-like structures that eventually engulfed the
nucleolar remnants (Fig. S8B). Notably, p53 was also localized to
the nucleolus following depletion of S6 in A549 cells (Fig. S8C).
Coimmunoprecipitation experiments from the nucleolar lysates
of ActD-treated A549 cells revealed that Mdm2 forms a complex
with p53, L5, L11, and PML, but not with S6, ﬁbrillarin, and UBF
(Fig. 5C).
It was reported that L11 down-regulation impairs the ability of
PML to localize to nucleoli upon doxorubicin treatment (36).
Here, we determined the requirement of L5 and L11 for nucleolar
localization of endogenous p53, Mdm2, and PML in response to
ActD treatment of A549 cells by immunoblotting (Fig. 5B). De-
pletion of either L5 or L11 impaired PML, p53, ac-p53, andMdm2
nucleolar accumulation (Fig. 5B). The expression levels of PML,
L5, and L11 within nucleoli in ActD-treated A549 cells were in-
dependent of p53 andMdm2 (Fig. 5B). Depletion of PML in these
cells did not prevent association of p53, Mdm2, L5, and L11 with
nucleoli, although it abolished accumulation of nucleolar ac-p53
(Fig. 5B). Thus, L5 and L11 are required for the recruitment of
PML, p53, ac-p53, and Mdm2 to the nucleolus upon ActD treat-
ment. Furthermore, our results show that L5- and L11-dependent
recruitment of PML to nucleoli is independent of p53 and Mdm2.
Interestingly, ac-p53 also accumulated in nonribosomal cytoplas-
mic and nucleoplasmic fractions in response to ActD, whereas
PML depletion abrogated this ac-p53 accumulation without sig-
niﬁcantly affecting p53 levels (Fig. S8D).
Together, these results suggest that continuous nucleolar ac-
cumulation of newly synthesized L5 and L11 together with PML,
Fig. 4. Accumulation of ribosome-free L5 and L11
upon ActD treatment is due to their mutual pro-
tection from proteasomal degradation. (A) A549
cells were transfected with the indicated siRNAs for
48 h and then treated with ActD for 5 h. Non-
ribosomal fractions were immunoblotted with the
indicated antibodies. (B) H1299 cells expressing YFP-
L11 (green) were transfected with L5 siRNA for 24 h
and then transfected with HA-Ub for 24 h. Cells
were then treated as indicated for 6 h, stained with
anti-HA antibody (red), and analyzed by CLSM.
(Scale bar, 5 μm.)
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Mdm2, and p53 have an important role in p53 activation upon
ActD treatment.
Discussion
Here, we demonstrate that L5 and L11 are critical mediators of
the activation of p53 by impaired ribosome biogenesis. Upon
exposure of cells to various ribosomal stressors, L5 and L11 are
unique among several RPs examined in being able to accumulate
in the nonribosomal fraction where they speciﬁcally bind Mdm2.
This further points to their speciﬁc role in activating p53. Im-
portantly, the L5/L11-Mdm2-p53 pathway has been convincingly
supported by an in vivo mouse model (37). RPs are among the
most abundant proteins in mammalian cells and are highly basic
proteins (29). If free from ribosomes, RPs can speciﬁcally or
nonspeciﬁcally interact with various macromolecules, including
proteins and RNA. Indeed, we were able to coimmunoprecipitate
all tested RPs with Mdm2 from the total cell lysate. Our results
are consistent with a recently published study in which a critical
role of L5 and L11, but not of L23 and S7, in p53 activation by
ActD and RP deﬁciencies was reported (23). However, our
ﬁndings differ from previously published studies that showed that
depletion of RPS7 (19–20), L23 (16–17), or L26 (18) com-
promises the induction of p53 after pharmacological inhibition of
ribosome biogenesis. We do not know the basis for these differ-
ences, which could be due to time of treatment with the drug,
siRNA sequences used, or cell-line differences. Given that these
studies have convincingly shown that S7, L23, and L26 interact
with Mdm2 and efﬁciently inhibit its ubiquitin ligase activity to-
ward p53 (16–20), we cannot rule out the possibility that they can
regulate p53 levels in certain cell types or upon exposure to
speciﬁc ribosomal biogenesis stressors, or with kinetics different
from L5 and L11. Additionally, these and possibly some other
RPs can trigger p53 activation when they are made in excess even
in the absence of “ribosomal biogenesis stress,” which may occur
in certain situations, as, for example, when c-Myc becomes hy-
peractivated (7) or after transfection of speciﬁc RPs (6).
Considerable controversy exists regarding the source of ribo-
somal stress-induced ribosome-free “p53-activating” RPs (6, 22,
38). Here, we showed that ribosome-free L5 and L11 are syn-
thesized upon ActD treatment. Although we do not detect
a signiﬁcant decrease in the levels of nucleolar L5 and L11 upon
ActD treatment, we cannot exclude the possibility that a small
portion of the newly synthesized nucleolar L5 and L11 may
contribute to the accumulation of ribosome-free L5 and L11. We
suggest that, in addition to new protein synthesis (Fig. 2C and
Fig. S4D) (22, 38), the interdependent protection of ribosome-
free L5 and L11 from proteasomal degradation may contribute
to their accumulation in the nonribosomal fraction and p53 ac-
tivation upon ribosomal stress (Fig. 5D and Fig. S7B).
It is known that RPs continue to be synthesized upon ActD
treatment and that they are rapidly degraded by proteasomes (29–
31). Here we showed that YFP-S6, YFP-L4, and endogenous S6
and S12 form nucleoplasmic aggregates in the presence of ActD
and MG132, suggesting that they are degraded by proteasomes
upon impairment of ribosome biogenesis. However, we failed to
demonstrate colocalization of ubiquitin with these aggregates,
implying that their degradation occurs through a proteasome-de-
pendent, ubiquitin-independent pathway (33). Previous studies
suggested that abnormal/misfolded proteins can be subjected to
ubiquitin-independent proteasomal degradation upon cellular
stress (33). It could be speculated that newly synthesized RPs,
when not bound to rRNA, assume abnormal 3D structures that
make them susceptible to degradation by the 20S proteasome,
without a requirement for ubiquitin conjugation (Fig. 5D) (33).
Fig. 5. Newly synthesized L5 and L11 colocalize with Mdm2, p53, and PML in the nucleolus upon ribosomal stress. (A) H1299 cells expressing YFP-L11 were
treated with ActD for 5 h in the presence or absence of CHX and then photobleached using a 488-nm laser. Time-lapse laser scanning microscopy was used to
monitor the recovery of the nucleolar ﬂuorescence signal. (Scale bar, 5 μm.) (B) A549 cells were transfected with siRNAs against L5, L11, p53, or PML for 48 h
and then left untreated or treated with ActD for 5 h. Puriﬁed nucleoli were immunoblotted with the indicated antibodies. (C) Nucleolar extracts (NoE) from
untreated or ActD-treated (5 h) A549 cells were immunoprecipitated with antibodies against Mdm2, L5, or L11. These immunoprecipitates and total cell lysate
(TCL) from ActD-treated A549 cells were immunoblotted with the indicated antibodies. (D) (Left) Under normal conditions, newly synthesized RPs of 40S (RPS)
and 60S (RPL) ribosomal subunits are imported into the nucleolus. (Middle) Upon impairment of ribosomal biogenesis, the majority of RPL and RPS are
synthesized, but they are degraded by nuclear 20S proteasomes. In contrast, L5 and L11 are not degraded, and they accumulate in the nonribosomal fraction,
where they bind Mdm2. L5 and L11 colocalize with Mdm2, p53, and PML in the nucleolus after impairment of ribosomal biogenesis, where full p53 activation
probably takes place. Less efﬁcient import of newly synthesized L5 and L11 into the nucleolus upon inhibition of ribosomal biogenesis may also contribute to
their accumulation in the nonribosomal fraction (indicated by dashed red arrow). (Right) In the absence of L5, ribosome-free L11 is degraded by proteasomes
upon ribosomal biogenesis stress, suggesting that L5 and L11 protect each other from degradation and explaining their mutual requirement in p53 activation.
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Such a mechanism would prevent potentially toxic accumulation
of unbound, free RPs in the nucleoplasm (30). This raises the
question as to why L5 and L11 are also not degraded upon ribo-
somal stress. The mutual protection of ribosome-free L5 and L11
from proteasomal degradation upon ribosomal stress may also
offer an explanation for their codependence in p53 up-regulation
(Fig. 5D) (21). It has been suggested that 5S rRNA forms a com-
plex with Mdm2, L5, and L11 (21, 39). However, further studies
will be required to fully understand a possible role of 5S rRNA in
L5- and L11-dependent p53 activation.
What is the role of the nucleolus in p53 activation by ribosomal
biogenesis stress? All tested ribosomal stressors caused functional
and/or structural alterations in the nucleolus. Despite evident
nucleolar disruption by ActD, we did not observe a signiﬁcant
decrease in the nucleolar levels of endogenous L5 and L11, which
is in contrast with other studies in which the fate of exogenous RPs
was followed (6). Surprisingly, endogenous L5 and L11 continue
to accumulate in the nucleolar remnants where they colocalize
with PML, Mdm2, and p53 under these conditions, suggesting
that the disrupted nucleoli may provide a platform for PML-
mediated posttranslational modiﬁcations and activation of p53
upon ribosomal stress (Fig. 5D) (34). An L11-dependent nucle-
olar localization of PML upon doxorubicin treatment has been
demonstrated (36). Here, we showed that L5- and L11-mediated
nucleolar localization of PML following ActD treatment is in-
dependent of Mdm2 and p53.
We speculate that activated p53 then relocalizes from nucleoli
to nucleoplasm and cytoplasm. Future studies will be required to
understand the relationship between nucleolar p53/Mdm2/PML/
L5/L11 and accumulation of nucleoplasmic and cytoplasmic p53.
In summary, we demonstrate that L5 and L11 are required for
p53 activation in response to various ribosomal biogenesis stres-
sors. Whereas other newly synthesized RPs are degraded by
proteasomes uponActD treatment, L5 and L11 accumulate in the
nonribosomal fraction where they interact with Mdm2. Impor-
tantly, we demonstrate that this selective accumulation of ribo-
some-free L5 and L11 is largely due to their mutual protection
from proteasomal degradation. The observation that newly syn-
thesized L5 and L11 continue to accumulate in nucleoli together
with Mdm2, p53, and PML even after impairment of ribosome
biogenesis suggests that the altered nucleoli may provide a site for
L5- and L11-dependent p53 activation. A potential implication of
our ﬁndings is that normal p53-activating functions of L5 and L11
might be compromised in various diseases (11).
Materials and Methods
Antibodies against RPs. Rabbit polyclonal antibodies against L11 were pro-
duced previously (5). Here, we generated polyclonal antibodies against S7,
S20, L5, L12, L23, and L26 and monoclonal antibodies against S3, S6, and S12
after immunization of rabbits or mice with speciﬁc His-tagged mouse RPs,
respectively. Details of other methods used in this research are described in
SI Materials and Methods.
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